NewLink Genetics Announces Presentation of Two Abstracts at AACR
March 01 2017 - 5:05PM
NewLink Genetics Corporation (NASDAQ:NLNK), a
biopharmaceutical company focused on bringing novel immuno-oncology
therapies to patients with cancer, today reported that two
abstracts on the company’s indoximod program will be presented at
the American Association for Cancer Research (AACR) 2017 Annual
Meeting in Washington, D.C.
- Clinical Trials Plenary Session: Abstract CT117 - Interim
analysis of the Phase 2 clinical trial of the IDO pathway inhibitor
indoximod in combination with pembrolizumab for patients with
advanced melanoma, to be presented during the Novel Immuno-Oncology
Agent Clinical Trials session, Tuesday April 4, 2017 10:30 a.m. -
12:45 p.m. ET.
- Poster Session: Abstract 4076 - A novel prodrug of
indoximod with enhanced pharmacokinetic properties, to be presented
during poster session PO.ET05.01 - Mechanistic Understanding of
Novel Anticancer Therapies, April 4, 2017 1 p.m. - 5 p.m. ET.
The complete text of Clinical Plenary Session abstracts that
have not been selected for the press program will be posted online
at 4:30 p.m. ET on Friday, March 31. The text of clinical trials
abstracts that have been selected for inclusion in the press
program will not be posted online until the date and time of
presentation.
"We are honored to have been selected by the AACR review
committee for the Clinical Trials Plenary Session at the upcoming
AACR meeting,” said Nicholas Vahanian, M.D., President and Chief
Medical Officer. “We look forward to sharing the data from
both of these abstracts.”
About NewLink Genetics Corporation
NewLink Genetics is a biopharmaceutical company at the
forefront of discovering, developing and commercializing novel
immuno-oncology product candidates to improve the lives of patients
with cancer. NewLink Genetics' product candidates are
designed to harness multiple components of the immune system to
combat cancer. For more information, please visit
http://www.newlinkgenetics.com
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements of
NewLink that involve substantial risks and uncertainties. All
statements, other than statements of historical fact, contained in
this press release are forward-looking statements, within the
meaning of The Private Securities Litigation Reform Act of 1995.
The words "anticipate," "believe," "estimate," "expect," "intend,"
"may," "plan," "target," "potential," "will," "could," "should,"
"seek" or the negative of these terms or other similar expressions
are intended to identify forward-looking statements, although not
all forward-looking statements contain these identifying
words. These forward-looking statements include, among
others, statements about results of its clinical trials for
product candidates; its timing of release of data from ongoing
clinical studies; its plans related to moving additional
indications into clinical development; and any other statements
other than statements of historical fact. Actual results or
events could differ materially from the plans, intentions and
expectations disclosed in the forward-looking statements that
NewLink makes due to a number of important factors, including those
risks discussed in "Risk Factors" and elsewhere in NewLink
Genetics' Annual Report on Form 10-K for the year
ended December 31, 2015 and other reports filed with
the U.S. Securities and Exchange Commission (SEC).
The forward-looking statements in this press release represent
NewLink's views as of the date of this press release. NewLink
anticipates that subsequent events and developments will cause its
views to change. However, while it may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so. You should,
therefore, not rely on these forward-looking statements as
representing NewLink Genetics' views as of any date subsequent to
the date of this press release.
Investors:
Beth Kurth
LaVoieHealthScience
617-374-8800, ext. 106
bkurth@lavoiehealthscience.com
Media:
Alison Chen
LaVoieHealthScience
617-374-8800, ext. 104
achen@lavoiehealthscience.com
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Mar 2024 to Apr 2024
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Apr 2023 to Apr 2024